Price Chart

Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
URL http://salariuspharma.com
Investor Relations URL http://ir.flex-pharma.com/phoenix.zhtml?c=253862&p=irol-irhome
HQ State/Province Texas
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
URL http://salariuspharma.com
Investor Relations URL http://ir.flex-pharma.com/phoenix.zhtml?c=253862&p=irol-irhome
HQ State/Province Texas
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A